Andrew Blank, DO
General Practice · Burlington, NJNPI 1184720542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$706
- AstraZeneca$590
- Lilly USA, LLC$327
- Otsuka America Pharmaceutical, Inc.$324
- AbbVie$311
- Astellas Pharma US Inc$231
- plus $3K from 51 others
What the payments were for
- Food & beverage$5,69698%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$149
How this compares
$5,789 in reported general payments places this provider in the 95th percentile of 2,978 general practice providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 640 | $262,163 |
| TrulicityDulaglutide | 72 | $103,000 |
| JanuviaSitagliptin Phosphate | 118 | $88,803 |
| OzempicSemaglutide | 46 | $75,546 |
| MresviaRsv Vaccine, Pref, Mrna/Pf | 220 | $67,818 |
| JardianceEmpagliflozin | 108 | $64,746 |
| GlatopaGlatiramer Acetate | 22 | $62,993 |
| XifaxanRifaximin | 36 | $50,848 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $46,286 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 140 | $43,755 |
| XareltoRivaroxaban | 78 | $37,663 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $34,896 |
| LinzessLinaclotide | 42 | $31,958 |
| RybelsusSemaglutide | 18 | $31,918 |
| RexultiBrexpiprazole | 12 | $28,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $97 | $305,918780 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $706 | $124,03577 claims |
| MerckJanuvia, Janumet | $177 | $123,698155 claims |
| Lilly USA, LLCTrulicity | $327 | $103,00072 claims |
| GSKShingrix, Breo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arexvy | $16 | $87,354248 claims |
| Boehringer IngelheimJardiance | $180 | $64,746108 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $154 | $50,84836 claims |
| AbbVieLinzess, Creon | $311 | $50,34466 claims |
| Johnson & JohnsonXarelto | $86 | $37,66378 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $324 | $28,02512 claims |
| NovartisEntresto | $93 | $20,10627 claims |
| AstraZenecaFarxiga | $590 | $13,64918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,978 general practice providers in New Jersey.
Other general practice in Burlington
- Ryan LakeClark$914K
- Hua-Yu Steven LiaoLodi$816K
- Howard GlazerFort Lee$636K
- Jeffrey ChustckieSomerset$165K
- John MinichettiEnglewood$142K
- Narenderan RajanHackettstown$135K
- Cindy YeungPiscataway$111K
- Andrew SpectorHaworth$75K
- Paul GoodmanPennington$42K
- Steven RasnerBridgeton$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.